Total serum bile acids predict therapy for HBeAg-negative chronic hepatitis B patients with borderline ALT and high HBV DNA.

MLA

Xie, Ran, et al. “Total Serum Bile Acids Predict Therapy for HBeAg-Negative Chronic Hepatitis B Patients with Borderline ALT and High HBV DNA.” Journal of Infection in Developing Countries, vol. 16, no. 8, Aug. 2022, pp. 1336–42. EBSCOhost, https://doi.org/10.3855/jidc.15915.

APA

Xie, R., Li, J., Zhang, H., Wang, L.-M., Huang, C.-R., & Chen, L.-W. (2022). Total serum bile acids predict therapy for HBeAg-negative chronic hepatitis B patients with borderline ALT and high HBV DNA. Journal of Infection in Developing Countries, 16(8), 1336–1342. https://doi.org/10.3855/jidc.15915

Chicago

Xie, Ran, Jiao Li, Hao Zhang, Ling-Mei Wang, Cheng-Rong Huang, and Li-Wen Chen. 2022. “Total Serum Bile Acids Predict Therapy for HBeAg-Negative Chronic Hepatitis B Patients with Borderline ALT and High HBV DNA.” Journal of Infection in Developing Countries 16 (8): 1336–42. doi:10.3855/jidc.15915.